Author

Marta Ávalos-Moreno

Université Libre de BruxellesORCID 0000-0002-9511-9711Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:gene regulatory network inference· 1 Approach:statistical model· 1

Frequent Co-Authors

Benjamin BeckiD· 2 shared Fabiana MoresiiD· 2 shared Xavier BisteauiD· 2 shared Andrea PavesiiD· 1 shared Aurora Vigato· 1 shared Diego Japon-RuiziD· 1 shared Diego Japón-Ruiz· 1 shared Eloine Garcia· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Benjamin BeckORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJul 17, 2026

Cisplatin-Induced Plasticity Drives Cross-Resistance to CDK4/6 Inhibitors and Reveals Targetable Vulnerabilities Through HDAC Inhibition in Esophageal Squamous Cell Carcinoma.

Marta Ávalos-Moreno, Aurora Vigato, Fabiana Moresi…·Xavier Bisteau

This study shows cisplatin resistance in ESCC leads to an immune-evasive, drug-tolerant state that confers cross-resistance to CDK4/6 inhibitors, which can be reversed by HDAC inhibitors.

DOI 10.64898/2026.07.17.738886

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCell Death and DiseasePeer-reviewedMay 29, 2026

CDK4/6 Inhibition Uncovers Subtype-Specific Vulnerabilities and Immune-Related Responses in Esophageal Squamous Cell Carcinoma.

Fabiana Moresi, Diego Japón-Ruiz, Matteo Serra…·Xavier Bisteau

This study evaluates palbociclib as a first-line therapy in eSCC, identifying response subtypes and showing immune activation through replication stress and DNA damage.

2 citations

humanbulk RNA-seq

𝕏 PostBluesky